Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate
2. 5-bromo-6-(imidazolidinylideneamino)quinoxaline
3. 5-bromo-6-(imidazolin-2-ylamino)quinoxaline
4. Agn 190342
5. Agn-190342
6. Agn190342
7. Alphagan
8. Alphagan P
9. Brimonidine
10. Brimonidine Purite
11. Brimonidine Tartrate (1:1)
12. Brimonidine Tartrate (1:1), (s-(r*,r*))-isomer
13. Brimonidine Tartrate, (r-(r*,r*))-isomer
14. Bromoxidine
15. Mirvaso
16. Ratio Brimonidine
17. Ratio-brimonidine
18. Sanrosa
19. Uk 14,304
20. Uk 14,304 18
21. Uk 14,304-18
22. Uk 14,30418
23. Uk 14,308
24. Uk 14304
25. Uk 14308
26. Uk-14,304-18
27. Uk-14,308
28. Uk-14304
29. Uk14,30418
30. Uk14,308
31. Uk14304
1. 70359-46-5
2. Alphagan
3. Brimonidine Tartarate
4. Brimonidine L-tartrate
5. Lumify
6. Brimonidinne Tartrate
7. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine (2r,3r)-2,3-dihydroxysuccinate
8. Mirvaso
9. 4s9cl2dy2h
10. Agn 190342-lf
11. Brimonidine D-tartarate
12. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(2r,3r)-2,3-dihydroxybutanedioic Acid
13. Uk-14304-18
14. Qoliana
15. Agn-190342-lf
16. Bromoxidine Tartrate
17. (5-bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate
18. Brimonidine Purite
19. Brimonidine Tartrate [usan]
20. (2r,3r)-2,3-dihydroxybutanedioic Acid; 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine
21. 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
22. 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1)
23. 59803-99-5
24. Ocu300
25. Unii-4s9cl2dy2h
26. Ocu-300
27. Agn-190342lf
28. Alphagan-p
29. Cd-07805
30. Agn 190342lf
31. Brimonidine Tartrate [usan:jan]
32. N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine;(2r,3r)-2,3-dihydroxybutanedioic Acid
33. Alphagan (tn)
34. 304 Tartrate
35. Uk-1430418
36. 5-bromo-n-
37. Uk14304 Tartrate
38. Agn190342 Tartrate
39. Uk 14304 (tartrate)
40. Agn190342 (tartrate)
41. Uk 14,304 (tartrate)
42. Schembl265607
43. Chembl1200389
44. Ex-a5415a
45. Hy-b0659a
46. Dtxsid70911371
47. Brimonidine Tartrate (jan/usan)
48. Brimonidine Tartrate [jan]
49. Hms3715p18
50. Act08633
51. Brimonidine D-tartrate [mi]
52. Brimonidine Tartrate [vandf]
53. Brimonidine Tartrate [mart.]
54. Mfcd07773072
55. Brimonidine Tartrate [usp-rs]
56. Brimonidine Tartrate [who-dd]
57. Akos016845265
58. Ccg-221278
59. Cs-4496
60. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine(2r,3r)-2,3-dihydroxysuccinate
61. As-18083
62. Brimonidine Tartrate [orange Book]
63. Brimonidine Tartrate [ep Monograph]
64. Brimonidine Tartrate [usp Monograph]
65. Cd07805/47
66. Cd-07805/47
67. Combigan Component Brimonidine Tartrate
68. A19740
69. D02076
70. Simbrinza Component Brimonidine Tartrate
71. Brimonidine Tartrate Component Of Combigan
72. 359b465
73. Brimonidine Tartrate Component Of Simbrinza
74. (4,5-bihydro-1h-imidazol-2-yl)quinoxalin-6-amine L-tartrate
75. 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl) Quinoxalin-6-amine Tartrate
76. 109826-56-4
| Molecular Weight | 442.22 g/mol |
|---|---|
| Molecular Formula | C15H16BrN5O6 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 441.02840 g/mol |
| Monoisotopic Mass | 441.02840 g/mol |
| Topological Polar Surface Area | 177 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 442 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Brimonidine tartrate |
| Drug Label | Brimonidine Tartrate Ophthalmic Solution, 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6 (2-imidazolidinylideneamino) quinoxaline L-tartrate. It is a white to sligh... |
| Active Ingredient | Brimonidine tartrate |
| Dosage Form | Solution/drops; Solution |
| Route | ophthalmic; Ophthalmic |
| Strength | 0.2%; 0.1% |
| Market Status | Tentative Approval; Prescription |
| Company | Apotex; Bausch And Lomb; Alcon Pharms; Sandoz; Akorn |
| 2 of 2 | |
|---|---|
| Drug Name | Brimonidine tartrate |
| Drug Label | Brimonidine Tartrate Ophthalmic Solution, 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6 (2-imidazolidinylideneamino) quinoxaline L-tartrate. It is a white to sligh... |
| Active Ingredient | Brimonidine tartrate |
| Dosage Form | Solution/drops; Solution |
| Route | ophthalmic; Ophthalmic |
| Strength | 0.2%; 0.1% |
| Market Status | Tentative Approval; Prescription |
| Company | Apotex; Bausch And Lomb; Alcon Pharms; Sandoz; Akorn |
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
D11AX21
API SUPPLIERS
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
Click Us!
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-10-26
Pay. Date : 2012-12-19
DMF Number : 15585
Submission : 2001-08-15
Status : Active
Type : II
Certificate Number : CEP 2014-331 - Rev 04
Issue Date : 2025-05-19
Type : Chemical
Substance Number : 2760
Status : Valid
Registration Number : 302MF10029
Registrant's Address : Na vlcinci 16/3 Klasterni Hradisko 779 00 Olomouc Czech Republic
Initial Date of Registration : 2020-02-13
Latest Date of Registration :
NDC Package Code : 63278-0488
Start Marketing Date : 2002-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Hiple Co., Ltd.
Registration Date : 2013-12-20
Registration Number : 20131220-200-I-380-02
Manufacturer Name : Farmak as
Manufacturer Address : Na Vlcinci 16/3, Klasterni Hradisko, 779 00 Olomouc, Czech Republic
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Jai Radhe Sales is your partner for all your sourcing needs.
Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
Maithri Drugs: Dedicated to your API needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36595
Submission : 2021-12-09
Status : Active
Type : II
Certificate Number : R0-CEP 2021-507 - Rev 00
Issue Date : 2023-07-04
Type : Chemical
Substance Number : 2760
Status : Valid
Date of Issue : 2024-02-12
Valid Till : 2027-02-11
Written Confirmation Number : WC-0407
Address of the Firm :
| Available Reg Filing : BR |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25051
Submission : 2011-07-05
Status : Active
Type : II
Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm :
NDC Package Code : 53747-036
Start Marketing Date : 2011-07-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22230
Submission : 2008-12-01
Status : Active
Type : II
Certificate Number : R0-CEP 2018-124 - Rev 00
Issue Date : 2020-05-14
Type : Chemical
Substance Number : 2760
Status : Valid
Date of Issue : 2025-09-29
Valid Till : 2028-08-09
Written Confirmation Number : WC-0072
Address of the Firm :
NDC Package Code : 66022-0110
Start Marketing Date : 2013-08-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17588
Submission : 2004-08-05
Status : Active
Type : II
Registration Number : 222MF10073
Registrant's Address : Digwal Village (Sy.Nos. 7-70, 70/1 and 70/2), Kohir Mandal, Sangareddy District-502 321, Telangana, India
Initial Date of Registration : 2010-02-25
Latest Date of Registration :
NDC Package Code : 55679-133
Start Marketing Date : 1999-05-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : AbbVie Korea Co., Ltd.
Registration Date : 2012-07-13
Registration Number : 20120713-200-I-93-01
Manufacturer Name : Piramal Pharma Limited
Manufacturer Address : Sy. Nos. 7-70, 70/1 & 70/2, Digwal Village, Kohir Mandal, Sangareddy Dist., 502321 Telangana, India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Brimonidine Tartrate is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Glaucoma.
Lead Product(s): Brimonidine Tartrate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 07, 2025
Lead Product(s) : Brimonidine Tartrate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brimonidine Tartrate is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 07, 2025
Details:
Brimonidine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.
Lead Product(s): Brimonidine Tartrate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 24, 2025
Lead Product(s) : Brimonidine Tartrate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy
Details : Brimonidine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 24, 2025
Details:
Under the terms of the licensing agreement, Théa will commercialize LNZ100 (aceclidine HCl) for the treatment of presbyopia in Canada.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Vizz
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Laboratoires Thea
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Licensing Agreement July 07, 2025
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Laboratoires Thea
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LENZ and Laboratoires Théa Announce Exclusive License Agreement for LNZ100 in Canada
Details : Under the terms of the licensing agreement, Théa will commercialize LNZ100 (aceclidine HCl) for the treatment of presbyopia in Canada.
Product Name : Vizz
Product Type : Miscellaneous
Upfront Cash : $70.0 million
July 07, 2025
Details:
Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Lotus Pharmaceutical
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 09, 2025
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Lotus Pharmaceutical
Deal Size : $125.0 million
Deal Type : Licensing Agreement
LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia
Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 09, 2025
Details:
Brimonidine Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Presbyopia.
Lead Product(s): Brimonidine Tartrate,Carbachol
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2025
Lead Product(s) : Brimonidine Tartrate,Carbachol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
Details : Brimonidine Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2025
Details:
Brimochol PF is a fixed-dose combination of carbachol and brimonidine tartrate that improves near vision in presbyopia by reducing pupil size to create a "pinhole effect," enhancing depth of focus.
Lead Product(s): Brimonidine Tartrate,Carbachol
Therapeutic Area: Ophthalmology Brand Name: Brimochol PF
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2025
Lead Product(s) : Brimonidine Tartrate,Carbachol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tenpoint Submits NDA To FDA for BRIMOCHOL PF in Presbyopia Treatment
Details : Brimochol PF is a fixed-dose combination of carbachol and brimonidine tartrate that improves near vision in presbyopia by reducing pupil size to create a "pinhole effect," enhancing depth of focus.
Product Name : Brimochol PF
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2025
Details:
Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Brinzolamide,Brimonidine Tartrate,Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Sengi
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2025
Lead Product(s) : Brinzolamide,Brimonidine Tartrate,Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Sengi
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
Details : Brinzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2025
Details:
Brimonidine Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Exanthema.
Lead Product(s): Brimonidine Tartrate,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2025
Lead Product(s) : Brimonidine Tartrate,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
Details : Brimonidine Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Exanthema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2025
Details:
Brimochol PF is a fixed-dose combination of carbachol and brimonidine tartrate that improves near vision in presbyopia by reducing pupil size to create a "pinhole effect," enhancing depth of focus.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Brimochol PF
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tenpoint Therapeutics Announces Phase 3 BRIMOCHOL™ PF Data for Presbyopia
Details : Brimochol PF is a fixed-dose combination of carbachol and brimonidine tartrate that improves near vision in presbyopia by reducing pupil size to create a "pinhole effect," enhancing depth of focus.
Product Name : Brimochol PF
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2025
Details:
The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, Brimochol PF, on track for NDA filing, with a promising pipeline of innovative therapeutics.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Brimochol PF
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Visus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 12, 2024
Lead Product(s) : Carbachol,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Visus Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
2 Eye Disease Biotechs Merge, Set Sights on FDA Approval
Details : The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, Brimochol PF, on track for NDA filing, with a promising pipeline of innovative therapeutics.
Product Name : Brimochol PF
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 12, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
5-BROMOQUINOXALIN-6-AMINE (BMTA)
CAS Number : 50358-63-9
End Use API : Brimonidine Tartrate
About The Company : Amara Labs Pvt Ltd is a WHO-GMP certified manufacturing company wholly owned by a team of technocrats with working experience of more than 20 years in Multi-Nat...
CAS Number : 6298-37-9
End Use API : Brimonidine Tartrate
About The Company : Founded in 2005, Hangzhou Deli Chemical Co., Ltd. is a specialized manufacturing factory of APIs, pharmaceutical intermediates and other chemicals, with product...
CAS Number : 50358-63-9
End Use API : Brimonidine Tartrate
About The Company : Founded in 2005, Hangzhou Deli Chemical Co., Ltd. is a specialized manufacturing factory of APIs, pharmaceutical intermediates and other chemicals, with product...
5-BROMO-N-(2-IMIDAZOLIN-2-YL)-6-QUINOXALINAMINE
CAS Number : CAS-59803-98-4
End Use API : Brimonidine Tartrate
About The Company : OM Pharmaceutical Industries is one of the established pharmaceutical company in India, which is engaged in manufacturing of Active Pharmaceutical Ingredients (...
CAS Number : 6298-37-9
End Use API : Brimonidine Tartrate
About The Company : Eyougene was incubated in Fudan Chemical and has grown into a leader in the field of chemical research and development, now based in the dynamic Lingang area of...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DKSH
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
Dosage Form : Cream / Lotion / Ointment
Grade : Topical
Application : Topical
Excipient Details : Boric acid is used as an antimicrobial preservative in topical formulations such as creams and ointments.
Pharmacopoeia Ref : EP
Technical Specs : 99.9 % Boric Acid (H3BO3)
Ingredient(s) : Boric Acid Excipient
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
Dosage Form : Tablet
Grade : Oral
Brand Name : Titanium dioxide PRETIOX ...
Application : Coloring Agents
Excipient Details : Titanium dioxide Pretiox AV01FG is used as a coloring and coating agent in oral solid dosage forms such as capsules, tablets, granules, and pellets.
Pharmacopoeia Ref : Fami-QS, Kosher, Halal, OHSAS ...
Technical Specs : Ti 59.95% and O 40.05%
Ingredient(s) : Titanium Dioxide
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
Dosage Form : Tablet
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Curia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Parenteral
Coating Systems & Additives
Direct Compression
Taste Masking
Solubilizers
Chewable & Orodispersible Aids
Disintegrants & Superdisintegrants
Topical
Granulation
Controlled & Modified Release
Thickeners and Stabilizers
Film Formers & Plasticizers
Co-Processed Excipients
Coloring Agents
API Stability Enhancers
Emulsifying Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Brimonidine Tartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brimonidine Tartrate manufacturer or Brimonidine Tartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brimonidine Tartrate manufacturer or Brimonidine Tartrate supplier.
PharmaCompass also assists you with knowing the Brimonidine Tartrate API Price utilized in the formulation of products. Brimonidine Tartrate API Price is not always fixed or binding as the Brimonidine Tartrate Price is obtained through a variety of data sources. The Brimonidine Tartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Brimonidine Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Brimonidine Tartrate, including repackagers and relabelers. The FDA regulates Brimonidine Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Brimonidine Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Brimonidine Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Brimonidine Tartrate supplier is an individual or a company that provides Brimonidine Tartrate active pharmaceutical ingredient (API) or Brimonidine Tartrate finished formulations upon request. The Brimonidine Tartrate suppliers may include Brimonidine Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Brimonidine Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Brimonidine Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Brimonidine Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Brimonidine Tartrate DMFs exist exist since differing nations have different regulations, such as Brimonidine Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Brimonidine Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Brimonidine Tartrate USDMF includes data on Brimonidine Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Brimonidine Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Brimonidine Tartrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Brimonidine Tartrate Drug Master File in Japan (Brimonidine Tartrate JDMF) empowers Brimonidine Tartrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Brimonidine Tartrate JDMF during the approval evaluation for pharmaceutical products. At the time of Brimonidine Tartrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Brimonidine Tartrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Brimonidine Tartrate Drug Master File in Korea (Brimonidine Tartrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Brimonidine Tartrate. The MFDS reviews the Brimonidine Tartrate KDMF as part of the drug registration process and uses the information provided in the Brimonidine Tartrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Brimonidine Tartrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Brimonidine Tartrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Brimonidine Tartrate suppliers with KDMF on PharmaCompass.
A Brimonidine Tartrate CEP of the European Pharmacopoeia monograph is often referred to as a Brimonidine Tartrate Certificate of Suitability (COS). The purpose of a Brimonidine Tartrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Brimonidine Tartrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Brimonidine Tartrate to their clients by showing that a Brimonidine Tartrate CEP has been issued for it. The manufacturer submits a Brimonidine Tartrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Brimonidine Tartrate CEP holder for the record. Additionally, the data presented in the Brimonidine Tartrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Brimonidine Tartrate DMF.
A Brimonidine Tartrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Brimonidine Tartrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Brimonidine Tartrate suppliers with CEP (COS) on PharmaCompass.
A Brimonidine Tartrate written confirmation (Brimonidine Tartrate WC) is an official document issued by a regulatory agency to a Brimonidine Tartrate manufacturer, verifying that the manufacturing facility of a Brimonidine Tartrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Brimonidine Tartrate APIs or Brimonidine Tartrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Brimonidine Tartrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Brimonidine Tartrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Brimonidine Tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Brimonidine Tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Brimonidine Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Brimonidine Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Brimonidine Tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Brimonidine Tartrate suppliers with NDC on PharmaCompass.
Brimonidine Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Brimonidine Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Brimonidine Tartrate GMP manufacturer or Brimonidine Tartrate GMP API supplier for your needs.
A Brimonidine Tartrate CoA (Certificate of Analysis) is a formal document that attests to Brimonidine Tartrate's compliance with Brimonidine Tartrate specifications and serves as a tool for batch-level quality control.
Brimonidine Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Brimonidine Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Brimonidine Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Brimonidine Tartrate EP), Brimonidine Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Brimonidine Tartrate USP).
